Todos os estudos
RecrutamentoFase IIIntervencionista

A clinical trial testing a new treatment called mRNA-4194 for people with Lynch syndrome

This study is testing a new treatment called mRNA-4194 for individuals with Lynch syndrome. Lynch syndrome increases the risk of certain cancers, particularly bowel cancer. The treatment aims to stimulate the body's immune system to recognise and eliminate specific abnormal cells before they develop into cancer. It does this by providing temporary instructions for the body to produce harmless protein pieces found in these abnormal cells, effectively 'training' the immune system. The trial is looking for people aged 18 and over with Lynch syndrome. It involves receiving injections of mRNA-4194, alongside health checks, blood tests, and colonoscopies, to assess its safety and how well it activates the immune system.

Em resumo

Status
Recrutamento
Fase
Fase II
Patrocinador
Universidade de Oxford
Meta de inscrição
110
Iniciar
17 Jul 2026
Conclusão estimada
02 Feb 2029

Sobre o que é este estudo?

This study is looking into a new treatment called mRNA-4194 for people who have a condition called Lynch syndrome. Lynch syndrome is a genetic condition where there's a fault in one of your genes. This fault means your body has a harder time fixing errors in your cells. Because of this, people with Lynch syndrome have a higher chance of developing certain types of cancer, most commonly in the bowel and, for women, the womb. Often, before bowel cancer develops, small growths called polyps can appear, which can be found and removed during a colonoscopy.

The mRNA-4194 treatment aims to give your immune system a helping hand. Your immune system is your body's natural defense against illness. This treatment tries to teach your immune system to recognise and get rid of those early abnormal cells – the ones that might turn into cancer – even before they become a problem. It works by giving your body temporary instructions to create small, harmless parts of proteins that are specific to these abnormal cells. This process is like a training exercise, helping your immune system learn to spot and destroy similar cells in the future.

This is a Phase II trial, meaning it's still in the earlier stages of testing in people. Researchers want to make sure the treatment is safe and to see if it can successfully train the immune system to fight off these abnormal cells. The hope is that this new approach could potentially prevent cancer from developing in individuals with Lynch syndrome, offering a new way to manage their condition.

Pontos principais

  • Tests new cancer prevention treatment (mRNA-4194) for Lynch syndrome.
  • Aims to train the immune system to destroy pre-cancerous cells.
  • Involves regular injections, blood tests, and colonoscopies.
  • Potential side effects include flu-like symptoms and injection site reactions.
  • Study will run from March 2026 to September 2029.
  • Run by University of Oxford and funded by Moderna.

Quem pode ser elegível?

To be considered for this study, you need to be at least 18 years old. You must also have a confirmed diagnosis of Lynch syndrome, meaning a specialist genetic test has shown you carry a specific faulty gene linked to the condition.

For the second part of the study, there's an additional requirement: during a screening colonoscopy (a procedure to look at the inside of your bowel), you must have at least one small bowel polyp. These polyps need to be between 2mm and 10mm in size and look like the type that can sometimes become cancerous. If you have these polyps, you would need to agree that they can be left in place temporarily, with a plan for them to be removed later in the study.

Polyps smaller than 2mm or larger than 10mm, or those that don't look like the type of concern, would be removed during your screening colonoscopy and would mean you wouldn't be able to participate in this specific part of the study.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Have you been diagnosed with Lynch syndrome by genetic testing?
  3. Are you comfortable with receiving regular injections?
  4. If joining Part 2, are you willing for small bowel polyps (2-10mm) to be temporarily left in place for monitoring?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you join this study, you will go through two main parts. In Part 1, up to 30 adults will receive several injections of mRNA-4194 into a muscle over 12 weeks. This helps researchers figure out a safe and effective dose. In Part 2, another 80-110 adults will receive several injections over six months, followed by a booster injection after a year. Throughout the study, you'll have regular appointments for health checks, blood samples, and colonoscopies to look for any changes in your bowel lining or detect polyps. These samples will be analysed by scientists to see if the treatment is successfully training your immune system. The study is expected to run from March 2026 to September 2029.

Riscos e benefícios potenciais

This is the first time mRNA-4194 has been given to people, so all side effects aren't fully known. However, based on similar treatments, you might experience flu-like symptoms such as tiredness, a mild fever, chills, headaches, and muscle or joint aches. You could also have soreness, swelling, or redness where the injection was given. Less commonly, more severe reactions at the injection site or even allergic reactions could occur. The main benefit of participating is helping doctors understand if mRNA-4194 is safe and if it can help your immune system prevent cancer in people with Lynch syndrome. Whilst polyps will be monitored closely, the study involves leaving some small polyps in place temporarily, which carries a small additional risk compared to standard care, although strict safety measures are in place to minimise this. You have the right to withdraw from the study at any time.

Localizações (1)

  • Churchill Hospital
    Aproximado
    Oxford, England

Perguntas frequentes

What is Lynch syndrome?

Lynch syndrome is a genetic condition that increases your risk of certain cancers, especially bowel and womb cancer, because your body has trouble repairing damaged cells.

What exactly does mRNA-4194 do?

mRNA-4194 is a new treatment that aims to teach your immune system to find and destroy abnormal cells before they can turn into cancer, by showing it specific protein pieces related to these cells.

What are the common side effects expected?

Common side effects are expected to be flu-like symptoms (like tiredness, mild fever, body aches) and reactions at the injection site (soreness, swelling, redness).

Will I have to have a colonoscopy?

Yes, participants will have colonoscopies as part of the study to monitor for changes in their bowel and to detect polyps.

Onde está ocorrendo o estudo?

The study is being run from the University of Oxford in the UK, but will be conducted in hospitals that specialise in clinical trials.

Como saber mais

OCTO INTERCEPT-Lynch Trial Team

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A clinical trial testing a new treatment called mRNA-4194 fo…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.